SEC Filings
Arbutus Argues Hepatitis B Cure Tally Could Rise To 11 From 10
Long-term follow-up showed five of eight patients maintained functional cure, while three lost that status but stayed partial cures.
SEC Filings
Long-term follow-up showed five of eight patients maintained functional cure, while three lost that status but stayed partial cures.
SEC Filings
Sales reached $269.3 million, but the operating loss widened to $34.2 million as expenses grew.
SEC Filings
Higher turnaround spending has produced uneven results, while management targets expanding margins in 2028 and double-digit returns in 2029.
SEC Filings
Liver-disease trials pushed development spending to $27.0 million, while the next FDA meeting is scheduled for December.
SEC Filings
Commercial-scale manufacturing validation is complete, with interim trial results and FDA pathway feedback expected in early 2027.
SEC Filings
Sales increased 11.8%, while nine-month care costs grew faster than revenue and debt stood at $1.5 billion.
SEC Filings
The company reached its debt target a quarter early and authorized up to $150 million in share repurchases.
SEC Filings
Lower staff and facility costs helped narrow the quarterly loss as Century prepares its cell therapies for human testing.
SEC Filings
Its fiscal 2027 sales forecast assumes $100 million from AI drug discovery, alongside a $75 million capital-spending plan.
SEC Filings
CARFAX sales grew 8%, while selling expenses and interest costs climbed in the company's first full standalone quarter.
SEC Filings
President Jason P. Ment will give more time to private-wealth, retirement-plan and insurance investment solutions.
SEC Filings
The Market Shaper designation assesses practical quantum computing ambitions, and Gartner says its ratings are opinions, not endorsements.